BioSante Pharmaceuticals has entered into an option agreement with an undisclosed pharmaceutical company to obtain a non-exclusive worldwide licence to use the former’s 2A / Furin technology in the expression of antibodies.

The patented technology allows for antibody cell line production, which subsequently reduces the time and cost of antibody production compared with existing commercial technologies.

The agreement, which is valid for six months, allows the pharmaceutical company to exercise the option to enter into a non-exclusive licence for the technology.

The antibody products market is estimated to be around $31bn in 2008.